We receive funding from a variety of sources that recognize the value of our high-impact research.
Ajay Chaudhuri, MBBS, MRCP(UK),FACE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism. Ajay Chaudhuri (Principal Investigator). Abbvie. 4/1/2024-12/1/2026.
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes, Moderate or Severe Renal Impairment with Inadequate. Ajay Chaudhuri (Principal Investigator). Lilly. 2/1/2024-12/1/2025.
QWINT-4: A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Display Injectio. Ajay Chaudhuri (Principal Investigator). Lilly. 9/1/2022-12/1/2025.
A Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple. Ajay Chaudhuri (Principal Investigator). Lilly. 9/1/2022-12/1/2025.
NATiV3: A randomized, double blind, placebo-controled, multicentre, Phase 3 study evaluating long term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosi. Ajay Chaudhuri (Principal Investigator). Inventiva. 5/1/2022-11/1/2028.
Synergy: A Randomized Double-Blind Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH). Ajay Chaudhuri (Principal Investigator). Lilly. 1/1/2020-12/1/2025.
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. Ajay Chaudhuri (Co-Investigator). JDRF. 1/1/2019-3/1/2026.
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. Husam Ghanim (Co-Principal Investigator). JDRF. $1,641,000. 1/1/2019-12/1/2024.
An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes. Husam Ghanim (Co-Investigator). AstraZeneca Pharmaceuticals LP. $735,000. 1/1/2018-12/1/2025.